Linked Life Data

2941687

Source:http://linkedlifedata.com/resource/pubmed/id/2941687

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1986-8-12
pubmed:abstractText
To study the duration of antibody persistence and protection provided by the hepatitis B vaccine, we followed 773 homosexual men for five years after completion of vaccination. Among the 635 participants in whom antibody levels above 9.9 sample ratio units (SRU) developed after vaccination, 15 percent lost antibody altogether, and in another 27 percent, antibody levels declined below 10 SRU within five years. The extent of the maximal antibody response strongly predicted the persistence of protective antibody. Hepatitis B infection occurred in 55 men; 8 of these infections were clinically important (characterized by the presence of the hepatitis B surface antigen and elevation of liver-enzyme levels), and two of the patients became hepatitis B virus carriers. The long-term risk of hepatitis B infection was inversely related to the maximal antibody response to vaccine. Most severe infections occurred among those who responded poorly or had no response to the vaccination. The risk of late infection with hepatitis B in those with an initially adequate vaccine response increased markedly when antibody levels decreased below 10 SRU, but only 1 of 34 late infections resulted in viremia and liver inflammation. A second series of vaccinations induced a moderate antibody response in 50 percent of the subjects who initially had no response or a poor response; however, the persistence of antibody was poor. Both antibody loss and the risk of severe disease should be considered when booster-dose strategies for the hepatitis B vaccine are being designed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0028-4793
pubmed:author
pubmed:issnType
Print
pubmed:day
24
pubmed:volume
315
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
209-14
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:2941687-Carrier State, pubmed-meshheading:2941687-Clinical Trials as Topic, pubmed-meshheading:2941687-Double-Blind Method, pubmed-meshheading:2941687-Follow-Up Studies, pubmed-meshheading:2941687-Hepatitis B, pubmed-meshheading:2941687-Hepatitis B Antibodies, pubmed-meshheading:2941687-Hepatitis B Core Antigens, pubmed-meshheading:2941687-Hepatitis B Surface Antigens, pubmed-meshheading:2941687-Hepatitis B Vaccines, pubmed-meshheading:2941687-Hepatitis B virus, pubmed-meshheading:2941687-Homosexuality, pubmed-meshheading:2941687-Humans, pubmed-meshheading:2941687-Immunization, Secondary, pubmed-meshheading:2941687-Male, pubmed-meshheading:2941687-Risk, pubmed-meshheading:2941687-Time Factors, pubmed-meshheading:2941687-Vaccination, pubmed-meshheading:2941687-Viral Hepatitis Vaccines
pubmed:year
1986
pubmed:articleTitle
Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial